6th Annual MedTech Access Leaders Forum 2017
5th - 7th, December, 2017, Berlin, Germany
In the increasingly cost-contained world of medical device market access, Payers (including Ministries of Health, Insurers private & public, Hospitals and local governments) are seeking to justify investment in new medical technologies.
Health Technology Assessment (HTA) agencies are now widely spreads across Europe assess new technologies and interventions not only on the grounds of clinical effectiveness, but also based on cost-effectiveness, cost-utility and cost-benefit, to ensure the payers’ limited funds are well invested. This HTA and value demonstration requirement has evolved the “commercialisation” landscape of medical devices across the world and this next barrier is one that all medical device companies seeking to gain reimbursement and approval from payers and tendering bodies, need to overcome.